UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Nature reviews. Cancer, ISSN 1474-175X, 07/2017, Volume 17, Issue 7, pp. 425 - 440
Life Sciences & Biomedicine | Oncology | Science & Technology | Myelodysplastic-Myeloproliferative Diseases - epidemiology | Genetic Predisposition to Disease | Prognosis | Myelodysplastic-Myeloproliferative Diseases - therapy | Epigenesis, Genetic | Humans | Gene Expression Regulation, Neoplastic | Hematopoietic Stem Cell Transplantation | Genotype | Myelodysplastic-Myeloproliferative Diseases - genetics | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Inflammation - complications | DNA Methylation | Phenotype | Signal Transduction - drug effects | Adult | Mutation | Child | Care and treatment | Gene mutations | Development and progression | Genetic aspects | Health aspects | Myelodysplastic syndromes | Algorithms | Pathogenesis | Disorders | Bone marrow | Epigenetics | Diagnostic systems | Myelodysplastic syndrome | Neoplasms | Tumors | Index Medicus
Journal Article
Cancer research (Chicago, Ill.), ISSN 0008-5472, 06/2005, Volume 65, Issue 11, pp. 4500 - 4505
Life Sciences & Biomedicine | Oncology | Science & Technology | Pharmacology. Drug treatments | Medical genetics | Biological and medical sciences | Medical sciences | Antineoplastic agents | Chromosome aberrations | Tumors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Cell Line | Dasatinib | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Models, Molecular | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Protein-Tyrosine Kinases - genetics | Animals | Fusion Proteins, bcr-abl | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 19, pp. 1781 - 1790
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Leukemia, Neutrophilic, Chronic - diagnosis | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - diagnosis | Humans | Janus Kinases - antagonists & inhibitors | Animals | Receptors, Colony-Stimulating Factor - genetics | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Signal Transduction - physiology | Mice | Protein Kinase Inhibitors - pharmacology | RNA, Small Interfering | Leukemia, Neutrophilic, Chronic - genetics | Mutation | Leukemia, Lymphoid - genetics | Protein-Tyrosine Kinases - antagonists & inhibitors | Dasatinib | Care and treatment | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Chronic myeloid leukemia | Diagnosis | Research | Drug therapy | Health aspects | Oncogenes | Tyrosine | BCR protein | Transformation | Myeloid leukemia | Colonies | Leukemia | Colleges & universities | Leukocytes (neutrophilic) | Patients | Lymphoma | Bone marrow | Janus kinase | Colony-stimulating factor | Protein-tyrosine kinase | Adapter proteins | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 02/2017, Volume 10, Issue 1, pp. 1 - 14
JAK | Janus kinase | Myelofibrosis | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Primary Myelofibrosis - mortality | Primary Myelofibrosis - drug therapy | Pyrazoles - therapeutic use | Splenomegaly - drug therapy | Double-Blind Method | Follow-Up Studies | Primary Myelofibrosis - complications | Risk Assessment | Humans | Survival Rate | Treatment Outcome | Fatigue - chemically induced | Diarrhea - chemically induced | Disease Progression | Janus Kinases - antagonists & inhibitors | Pyrazoles - administration & dosage | Sepsis - chemically induced | Pneumonia - chemically induced | Pyrazoles - adverse effects | Treatment outcome | Drug therapy | Analysis | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 10/2007, Volume 110, Issue 7, pp. 2242 - 2249
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Chromosome aberrations | Medical genetics | Recurrence | Cell Proliferation | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Piperazines - chemistry | Pyrimidines - chemistry | Point Mutation - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Risk Factors | Models, Molecular | Piperazines - therapeutic use | Mutation - genetics | Imatinib Mesylate | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Benzamides | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2019, Volume 381, Issue 24, pp. 2315 - 2326
d_article_not_yet_freely_accessible | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Niacinamide - analogs & derivatives | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Niacinamide - pharmacokinetics | Adult | Female | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Pyrazoles - adverse effects | Niacinamide - adverse effects | Logistic Models | Niacinamide - administration & dosage | Fusion Proteins, bcr-abl - genetics | Pyrazoles - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Aged | Mutation | Tyrosine | Thrombocytopenia | Headache | Myeloid leukemia | Leukemia | Arthralgia | Pancreatitis | Chronic myeloid leukemia | Lipase | Kinases | Patients | Philadelphia chromosome | Side effects | Allosteric properties | Cytogenetics | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article
Cancer cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
CHEMBIO | HUMDISEASE | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice |